Navigation Links
AcelRx to Present at the Lazard 6th Annual Healthcare Conference
Date:11/13/2009

REDWOOD CITY, Calif., Nov. 13 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced that Thomas Schreck, President & Chief Executive Officer, and Pamela Palmer, MD, PhD, Chief Medical Officer, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference to be held November 17-18, 2009, at The St. Regis Hotel, New York.

AcelRx Pharmaceuticals' presentation is scheduled for Wednesday, November 18, at 3:15 PM Eastern Time.

Mr. Schreck and Dr. Palmer will be providing an update on three market-driven AcelRx products: ARX-01, Sufentanil NanoTab PCA System, a proprietary drug/device product which offers a non-invasive alternative to intravenous patient-controlled analgesia (IV PCA) for the management of acute post-operative pain in patients requiring opioid analgesia during hospitalization; ARX-02, Sufentanil NanoTab Breakthrough Pain Management System for treatment of cancer pain, a proprietary sublingual dosage form of sufentanil; and ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet need for a non-invasive product to provide mild sedation, anxiolysis and analgesia with rapid onset of action for painful and anxiety-producing office-based surgical procedures.

AcelRx has reported positive Phase 2 results from three studies with ARX-01 and successfully completed an End-of-Phase 2 meeting with the FDA in late October, 2009.

Mr. Schreck will discuss anticipated Company milestones for the remainder of 2009 and those expected to occur in 2010.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of currently approved compounds. For additional information about AcelRx Pharmaceuticals visit http://www.acelrx.com.

SOURCE AcelRx Pharmaceuticals, Inc.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
2. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
3. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
4. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
5. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
6. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
7. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
8. West to Present at Investor Conference
9. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10. John Madden to Honor the NFLs Best Offensive Linemen with Madden Most Valuable Protectors Award Presented by Prilosec OTC(R)
11. Chimerix to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
Breaking Medicine News(10 mins):